6.5 C
New York
Thursday, September 29, 2022

The partnership between Novartis and Microsoft seems promising

Must Read

Breaks In ‘junk’ DNA Yield New Clues To Treat Neurological Disorders

Contrary to earlier theories, "junk" DNA is much more vulnerable to breaks from oxidative genomic damage, which...

Newly-discovered Fossil “Treasure Hoard” Fills In Missing Pieces Of The Tree Of Life

Researchers from the Chinese Academy of Sciences' Institute of Vertebrate Paleontology and Paleoanthropology (IVPP) have recently found...

Remains Of A 439-Million-Year-Old Toothed Fish Challenge Long-Held Beliefs About Vertebrate Evolution

An international team of scientists has found toothed fish remains that date back 439 million years, which...
Amit Kumar
Amit Kumar is the editor-in-chief and founder of Revyuh.com. He has been shaping the future of Revyuh.com in terms of content, text, and personnel. When he's not writing, Amit enjoys watching Netflix, embarrassing himself with chess, or you'll find him exploring the world’s largest general scientific society The American Association for the Advancement of Science (AAAS). Currently, Amit lives in New Delhi, India. Email: amit.kumar (at) revyuh (dot) com ICE : 00 91 (0) 99580 61723

Novartis is in the process of digitally upgrading. Since Bertrand Bodson joined the newly created post of Chief Digital Officer in January 2018, a number of projects have been launched that will take the pharmaceutical company into the new era of analyzing large amounts of data. Up to now, the necessary capacity expansion has mainly taken place in-house, or they have teamed up with small start-up companies, for example to test new instruments in the field of artificial intelligence.

Three-country laboratory

Now, Novartis is embarking on a bigger leap and starting a cooperation with IT group Microsoft. The goal of the five-year collaboration is to bundle the artificial intelligence capabilities of the two companies, thereby triggering an innovation boost in the pharmaceutical business. The plan is to create an AI Innovation Lab with locations on the Novartis campus in Basel, the company’s Global Service Center in Dublin, and the Microsoft Research Lab in the UK. Bodson did not comment on the staffing levels of this new facility and the size of the planned investments. He emphasized, however, that both companies contributed funds to the project.

On the one hand, the increased technological potential should serve to accelerate the development of new drugs and their market introduction. Thanks to artificial intelligence, it is hoped that it will be possible to efficiently process the vast amounts of clinical data generated in studies or in the treatment of patients in hospitals. In this way, new interactions of substances and new therapeutic options are likely to be discovered. On the other hand, the company’s field staff should have data-driven analytical tools in their contacts with physicians and hospitals that allow them to present better therapeutic options for patients or better drug dosages.

Success is not guaranteed

The partnership between Novartis and Microsoft seems promising. Whether the potential can actually be realized is another question. It is recalled that in 2014 Basler and Internet company Google decided to develop and launch an “intelligent contact lens”. The plan was to use a lens and microchip lens that could be used for medical purposes such as diabetes treatment. The project was unsuccessful and ended at the end of 2018 sang- and soundless. The Google Novartis project is barely comparable to the Microsoft Novartis project, but shows that such cross-industry collaboration is not free of pitfalls.

- Advertisement -


Please enter your comment!
Please enter your name here

- Advertisement -

Latest News

- Advertisement -

More Articles Like This

- Advertisement -